{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:28:11Z","timestamp":1784334491727,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biopha.2018.08.044","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T14:25:46Z","timestamp":1534775146000},"page":"712-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2"],"prefix":"10.1016","volume":"107","author":[{"given":"Shufeng","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.08.044_bib0005","first-page":"632","article-title":"New therapies for ovarian Cancer","volume":"16","author":"Armstrong","year":"2018","journal-title":"J. Compr. Cancer Netw."},{"key":"10.1016\/j.biopha.2018.08.044_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41420-018-0063-4","article-title":"Cordycepin induces apoptosis of human ovarian cancer cells by inhibiting CCL5-mediated Akt\/NF-kappaB signaling pathway","volume":"4","author":"Cui","year":"2018","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2018.08.044_bib0015","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3802\/jgo.2018.29.e63","article-title":"Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center","volume":"29","author":"Lee","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2018.08.044_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5468\/ogs.2018.61.3.352","article-title":"Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer","volume":"61","author":"Shin","year":"2018","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/j.biopha.2018.08.044_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejogrb.2018.05.024","article-title":"Diaphragm disease in advanced ovarian cancer: predictability of pre-operative imaging and safety of surgical intervention","volume":"226","author":"Pounds","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.biopha.2018.08.044_bib0030","doi-asserted-by":"crossref","first-page":"16053","DOI":"10.3390\/ijms131216053","article-title":"MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer","volume":"13","author":"Li","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2018.08.044_bib0035","doi-asserted-by":"crossref","first-page":"664","DOI":"10.14348\/molcells.2014.0121","article-title":"MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer","volume":"37","author":"Guo","year":"2014","journal-title":"Mol. Cells"},{"key":"10.1016\/j.biopha.2018.08.044_bib0040","first-page":"5048","article-title":"MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4","volume":"9","author":"Yu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2018.08.044_bib0045","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1159\/000489591","article-title":"MicroRNA-135a inhibits nasopharyngeal carcinoma cell proliferation through targeting Interleukin-17","volume":"46","author":"Wang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2018.08.044_bib0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13258-017-0624-6","article-title":"Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes","volume":"40","author":"Ahmad","year":"2018","journal-title":"Genes Genomics"},{"key":"10.1016\/j.biopha.2018.08.044_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3233\/CBM-170566","article-title":"MiR-135a-5p modulates biological functions of thyroid carcinoma cells via targeting VCAN 3\u2019-UTR","volume":"20","author":"Zhao","year":"2017","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.biopha.2018.08.044_bib0060","first-page":"1","article-title":"MiR-135a-5p represses proliferation of HNSCC by targeting HOXA10","author":"Guo","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2018.08.044_bib0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1166\/jbn.2018.2579","article-title":"miR-135a-5p and miR-124-3p inhibit malignancy of glioblastoma by downregulation of syndecan binding protein","volume":"14","author":"Lin","year":"2018","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.biopha.2018.08.044_bib0070","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/cas.12463","article-title":"MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer","volume":"105","author":"Zhou","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2018.08.044_bib0075","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/cas.13210","article-title":"MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer","volume":"108","author":"Fukagawa","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2018.08.044_bib0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1724600817753094","article-title":"The role of selected chemokines and their specific receptors in pancreatic cancer","volume":"33","author":"Lukaszewicz-Zajac","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.biopha.2018.08.044_bib0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.coi.2018.03.004","article-title":"Chemokines and cancer: new immune checkpoints for cancer therapy","volume":"51","author":"Karin","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2018.08.044_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/01.3001.0010.5246","article-title":"An association of the MCP-1 and CCR2 single nucleotide polymorphisms with colorectal cancer prevalence","volume":"89","author":"Walczak","year":"2017","journal-title":"Pol Przegl Chir"},{"key":"10.1016\/j.biopha.2018.08.044_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2018.08.044_bib0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1535-7163.MCT-16-0124","article-title":"Blocking the CCL2-CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular Cancer in a mouse model","volume":"16","author":"Teng","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2018.08.044_bib0105","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2018.08.044_bib0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2009.11.009","article-title":"CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis","volume":"21","author":"Zhang","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2018.08.044_bib0115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1080\/19336918.2015.1035504","article-title":"Haptoglobin and CCR2 receptor expression in ovarian cancer cells that were exposed to ascitic fluid: exploring a new role of haptoglobin in the tumoral microenvironment","volume":"9","author":"Garibay-Cerdenares","year":"2015","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.biopha.2018.08.044_bib0120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jcb.21220","article-title":"CCR2 expression correlates with prostate cancer progression","volume":"101","author":"Lu","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2018.08.044_bib0125","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.12659\/MSM.906616","article-title":"Long noncoding RNA taurine-upregulated gene1 (TUG1) promotes tumor growth and metastasis through TUG1\/Mir-129-5p\/astrocyte-elevated gene-1 (AEG-1) axis in malignant melanoma","volume":"24","author":"Long","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2018.08.044_bib0130","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.13539","article-title":"KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway","volume":"109","author":"Xu","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2018.08.044_bib0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.biopha.2018.05.077","article-title":"MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met\/AKT\/mTOR signaling pathway","volume":"104","author":"Dai","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.08.044_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13048-018-0414-z","article-title":"Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer","volume":"11","author":"Drakes","year":"2018","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.biopha.2018.08.044_bib0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbrc.2015.07.145","article-title":"MiR-135a inhibits migration and invasion and regulates EMT-related marker genes by targeting KLF8 in lung cancer cells","volume":"465","author":"Shi","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2018.08.044_bib0150","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/carcin\/bgu032","article-title":"miR-135a leads to cervical cancer cell transformation through regulation of beta-catenin via a SIAH1-dependent ubiquitin proteosomal pathway","volume":"35","author":"Leung","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2018.08.044_bib0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12964-017-0209-7","article-title":"MicroRNA-135a regulates NHE9 to inhibit proliferation and migration of glioblastoma cells","volume":"15","author":"Gomez Zubieta","year":"2017","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.biopha.2018.08.044_bib0160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12935-016-0328-z","article-title":"miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1","volume":"16","author":"Zeng","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biopha.2018.08.044_bib0165","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4161\/cbt.18943","article-title":"MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation","volume":"13","author":"Wu","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2018.08.044_bib0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12967-015-0438-8","article-title":"Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer","volume":"13","author":"Mao","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2018.08.044_bib0175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1359-6101(01)00033-8","article-title":"Chemokines in cancer","volume":"13","author":"Vicari","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2018.08.044_bib0180","doi-asserted-by":"crossref","first-page":"36593","DOI":"10.1074\/jbc.M112.365999","article-title":"CCL2\/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42\/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms","volume":"287","author":"Fang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2018.08.044_bib0185","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ijc.29049","article-title":"TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2\/CCR2 signaling","volume":"136","author":"Ding","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2018.08.044_bib0190","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1078-0432.CCR-10-2325","article-title":"Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells","volume":"17","author":"Rosano","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2018.08.044_bib0195","article-title":"EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.08.044_bib0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.12659\/MSM.901667","article-title":"Targeting of Wnt\/beta-catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Med. Sci. Monit."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218338526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218338526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:33:19Z","timestamp":1766025199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218338526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":40,"alternative-id":["S0753332218338526"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.044","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}